Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
2024年8月15日 - 5:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 000-56234
NOTIFICATION OF LATE FILING
☐ Form 10-K |
☐ Form 11-K |
☐ Form 20-F |
☒ Form 10-Q |
☐ Form 10-D |
☐ Form N-SAR |
☐ Form N-CSR |
|
|
|
For Period Ended: June 30, 2024
☐ Transition Report on Form 10-K |
☐ Transition Report on Form 20-F |
☐ Transition Report on Form 11-K |
☐ Transition Report on Form 10-Q |
For the Transition Period Ended:
_______________________________________ |
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
If the notification relates to a
portion of the filing checked above, identify the item(s) to which the
notification relates:__________________________________
PART I
REGISTRANT
INFORMATION
Nika
Pharmaceuticals, Inc. |
Full name of registrant |
2269 Merrimack Valley Avenue |
Henderson, NV
89044 |
Address of principal executive office city, state and zip
code |
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
|
(a) |
The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable effort or
expense; |
☒ |
(b) |
The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or
portion thereof will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q or subject distribution report on Form
10-D, or portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and |
|
(c) |
The accountants statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable. |
PART III
NARRATIVE
State below in reasonable detail
the reasons why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR or the
transition report portion thereof could not be filed within the prescribed time
period.
The Company is unable to file, without unreasonable effort or
expense, its Quarterly Report on Form 10-Q for the period ended June 30, 2024
(the Form 10-Q). Additional time is needed to allow the Companys independent
registered public accounting firm to complete its review of the consolidated
financial statements included in the Form 10-Q. The Company intends to file the
Form 10-Q by or before August 19, 2024.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to
this notification
Clifford Redekop |
|
(702) |
|
326-3615 |
(Name)
|
|
(Area Code) |
|
(Telephone Number) |
(2) Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period
that the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s).
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
Nika Pharmaceuticals, Inc.
Name of Registrant as Specified
in Charter.
Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: August 14, 2024 |
|
By: |
/s/
Dimitar Savov |
|
|
|
Dimitar Savov, Chief Executive Officer
|
Nika Pharmaceuticals (PK) (USOTC:NKPH)
過去 株価チャート
から 7 2024 まで 8 2024
Nika Pharmaceuticals (PK) (USOTC:NKPH)
過去 株価チャート
から 8 2023 まで 8 2024